Active clinical trials using interventions that target/impact DCs
| ID . | Condition . | Intervention . | Phase . | Study type . | Sponsor . |
|---|---|---|---|---|---|
| HDAC inhibition | |||||
| NCT00810602 | aGVHD | Vorinostat plus tacrolimus and mycophenolate after RIC related donor allogeneic transplant; prevention | II | Single-agent, open-label, non-randomized safety/efficacy | University of Michigan Cancer Center |
| NCT01111526 | aGVHD | Panobinostat (LBH589) plus corticosteroids; initial treatment | I/II | Non-randomized, open-label, safety/efficacy | H. Lee Moffitt Cancer Center and Research Institute |
| Proteasome inhibition | |||||
| NCT01158105 | Steroid-refractory cGVHD | Bortezomib; treatment | II | Single-agent, open-label, safety/efficacy | Baylor Research Institute |
| NCT00670423 | GVHD | Bortezomib plus tacrolimus and sirolimus after allogeneic PBSC transplant; prevention | I | Single-agent, open-label, safety | Indiana University School of Medicine |
| NCT01323920 | aGVHD | Bortezomib plus tacrolimus and methotrexate after myeloablative allogeneic SCT without HLA-matched related donor; prevention | II | Single-agent, open-label, safety/efficacy | Dana-Farber Cancer Institute |
| NCT01163786 | Bronchiolitis obliterans (cGVHD) | Bortezomib; treatment | II | Single-agent, open-label, safety/efficacy | Northwestern University |
| Antibody therapy | |||||
| NCT01012492 | aGVHD | Abatacept (CTLA4-Ig) plus cyclosporine and methotrexate after unrelated donor HSCT; prevention | II | Single group, open-label, safety | Emory University |
| Cellular therapy | |||||
| NCT00603330 | Grade II to IV steroid-refractory aGVHD | MSCs; treatment | II | Single-agent, open-label, efficacy | University Hospital of Liege |
| NCT00827398 | Grade II to IV steroid-refractory aGVHD | MSCs; treatment | I/II | Single-agent, open-label, safety/efficacy | UMC Utrecht |
| NCT00759018 | Grade II to IV steroid-refractory aGVHD | MSCs; treatment | NA | Expanded access (pediatrics) | Osiris Therapeutics |
| NCT00826046 | Grade II to IV steroid-refractory aGVHD | MSCs; treatment | NA | Expanded access (adults) | Osiris Therapeutics |
| NCT01522716 | Steroid-refractory cGVHD | MSCs; treatment | I | Single-agent, open-label, safety/efficacy | Karolinska Institute |
| NCT01045382 | GVHD | MSCs versus placebo in HLA-mismatched allogeneic transplant after non-myeloablative conditioning; prevention | II | Randomized, double-blind, safety/efficacy | University Hospital of Liege |
| NCT01222039 | cGVHD | Conventional therapy versus conventional therapy plus MSCs derived from adipose tissue; treatment | I/II | Multicenter, randomized, safety/efficacy | Fundacion Progreso y Salud, Spain |
| NCT00957931 | GVHD | Haploidentical MSCs in MUD HCT in patients with high-risk non-malignant RBC disorders after RIC; prevention | II | Non-randomized, open-label, efficacy | Stanford University |
| NCT01050764 | GVHD | Allogeneic Treg plus allogeneic conventional T cells after allogeneic MAC HCT with haploidentical related donor for patients with hematologic malignancies; prevention | II | Non-randomized, open-label, safety/efficacy | Stanford University |
| NCT00935597 | GVHD | Host DC infusion after allogeneic SCT for prevention or treatment of relapsed disease in patients with advanced hematologic malignancies | I | Non-randomized, open-label, safety/efficacy | Mt Sinai School of Medicine |
| ID . | Condition . | Intervention . | Phase . | Study type . | Sponsor . |
|---|---|---|---|---|---|
| HDAC inhibition | |||||
| NCT00810602 | aGVHD | Vorinostat plus tacrolimus and mycophenolate after RIC related donor allogeneic transplant; prevention | II | Single-agent, open-label, non-randomized safety/efficacy | University of Michigan Cancer Center |
| NCT01111526 | aGVHD | Panobinostat (LBH589) plus corticosteroids; initial treatment | I/II | Non-randomized, open-label, safety/efficacy | H. Lee Moffitt Cancer Center and Research Institute |
| Proteasome inhibition | |||||
| NCT01158105 | Steroid-refractory cGVHD | Bortezomib; treatment | II | Single-agent, open-label, safety/efficacy | Baylor Research Institute |
| NCT00670423 | GVHD | Bortezomib plus tacrolimus and sirolimus after allogeneic PBSC transplant; prevention | I | Single-agent, open-label, safety | Indiana University School of Medicine |
| NCT01323920 | aGVHD | Bortezomib plus tacrolimus and methotrexate after myeloablative allogeneic SCT without HLA-matched related donor; prevention | II | Single-agent, open-label, safety/efficacy | Dana-Farber Cancer Institute |
| NCT01163786 | Bronchiolitis obliterans (cGVHD) | Bortezomib; treatment | II | Single-agent, open-label, safety/efficacy | Northwestern University |
| Antibody therapy | |||||
| NCT01012492 | aGVHD | Abatacept (CTLA4-Ig) plus cyclosporine and methotrexate after unrelated donor HSCT; prevention | II | Single group, open-label, safety | Emory University |
| Cellular therapy | |||||
| NCT00603330 | Grade II to IV steroid-refractory aGVHD | MSCs; treatment | II | Single-agent, open-label, efficacy | University Hospital of Liege |
| NCT00827398 | Grade II to IV steroid-refractory aGVHD | MSCs; treatment | I/II | Single-agent, open-label, safety/efficacy | UMC Utrecht |
| NCT00759018 | Grade II to IV steroid-refractory aGVHD | MSCs; treatment | NA | Expanded access (pediatrics) | Osiris Therapeutics |
| NCT00826046 | Grade II to IV steroid-refractory aGVHD | MSCs; treatment | NA | Expanded access (adults) | Osiris Therapeutics |
| NCT01522716 | Steroid-refractory cGVHD | MSCs; treatment | I | Single-agent, open-label, safety/efficacy | Karolinska Institute |
| NCT01045382 | GVHD | MSCs versus placebo in HLA-mismatched allogeneic transplant after non-myeloablative conditioning; prevention | II | Randomized, double-blind, safety/efficacy | University Hospital of Liege |
| NCT01222039 | cGVHD | Conventional therapy versus conventional therapy plus MSCs derived from adipose tissue; treatment | I/II | Multicenter, randomized, safety/efficacy | Fundacion Progreso y Salud, Spain |
| NCT00957931 | GVHD | Haploidentical MSCs in MUD HCT in patients with high-risk non-malignant RBC disorders after RIC; prevention | II | Non-randomized, open-label, efficacy | Stanford University |
| NCT01050764 | GVHD | Allogeneic Treg plus allogeneic conventional T cells after allogeneic MAC HCT with haploidentical related donor for patients with hematologic malignancies; prevention | II | Non-randomized, open-label, safety/efficacy | Stanford University |
| NCT00935597 | GVHD | Host DC infusion after allogeneic SCT for prevention or treatment of relapsed disease in patients with advanced hematologic malignancies | I | Non-randomized, open-label, safety/efficacy | Mt Sinai School of Medicine |
PBSC indicates peripheral blood stem cell; MUD, matched-unrelated donor; RBC, red blood cells; and NA, not applicable.